On November 21, 2024, John Kelly, Chief Financial Officer of Precision BioSciences Inc, purchased 3,000 shares of the company. Following this transaction, the insider now owns a total of 38,073 shares. The purchase was documented in an SEC Filing.
Precision BioSciences Inc (DTIL, Financial) is a biotechnology company focused on developing genome editing technologies to treat genetic disorders and cancers. The company aims to provide innovative solutions in the field of precision medicine.
The insider transaction history for Precision BioSciences Inc indicates that there has been one insider buy and 13 insider sells over the past year. This recent purchase by John Kelly marks the only insider buy within this timeframe.
On the day of the purchase, shares of Precision BioSciences Inc were trading at $6.76, resulting in a market cap of $49.858 million. The company's price-earnings ratio stands at 119.67, which is higher than the industry median of 26.81 and also higher than the company's historical median price-earnings ratio.
The GF Value of Precision BioSciences Inc is estimated at $14.43, giving it a price-to-GF-Value ratio of 0.47. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company's past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
